Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek March 11, 2010 Margaret Cronin Fisk et al.	Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.
Chemistry World March 26, 2014 Phillip Broadwith	$1.2bn J&J deceptive marketing fine overturned The Arkansas Supreme Court has overturned a lower court's fine of $1.2 billion, imposed on Johnson & Johnson's subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone).
BusinessWeek February 26, 2007 Arlene Weintraub	Pushing The Pills A Bit Too Hard Feds and states are putting drug marketing under the microscope and seeing abuse.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
BusinessWeek April 25, 2005 Barrett & Carey	"Off-Label" Drugs: J&J Is Pushing The Envelope Recommending uses for its drugs not intended when approved by the FDA.
Pharmaceutical Executive January 1, 2006 Cinquegrana & Lloyd	Legal: Shifting Perspective on Off-Label Promotion A recent court case points to the government's shifting perspective on how it prosecutes companies for promoting off-label. Instead of criminal charges, hefty corporate integrity agreements might be in store.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool August 24, 2007 Brian Orelli	Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note.
BusinessWeek October 18, 2004 John Carey	"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be?
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
Chemistry World June 6, 2013 Phillip Broadwith	Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud.
The Motley Fool December 3, 2007 Brian Orelli	More Heartburn From J&J's Natrecor The company takes a $440 million writedown as the heart drug continues to falter. Investors, Johnson & Johnson has a way to go before it can turn things around.
BusinessWeek April 11, 2005 Amy Barrett	A Prescription For Trouble At J&J? Johnson & Johnson faces controversy over its heart failure drug Natrecor.
BusinessWeek April 23, 2007 Arlene Weintraub	Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them.
BusinessWeek March 31, 2011 David Voreacos et al.	Johnson & Johnson's Quality Catastrophe After 50-plus product recalls in 15 months, the $60 billion company is fighting to clear its once-trusted name.
The Motley Fool February 23, 2009 Brian Orelli	The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor.
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
The Motley Fool October 30, 2007 Brian Lawler	Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
The Motley Fool August 14, 2009 Brian Orelli	The Schizophrenic Drug Approval Schering's drug gets a thumbs-up.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
Chemistry World January 9, 2014 Phillip Broadwith	Novartis in the spotlight in mis-selling investigations Swiss firm Novartis is being sued by the attorney general's office in New York, US, for alleged mis-selling of its iron-chelating drug Exjade (deferasirox).
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
Health April 2007 Joan Raymond	The "New" Diet Pills Drugs for depression, anxiety, and seizures are being used for weight loss. But do they work and are they safe?
The Motley Fool December 6, 2007 Brian Orelli	An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
BusinessWeek December 11, 2006 Michael Arndt	Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool January 15, 2010 Brian Orelli	The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Chemistry World May 29, 2015 Phillip Broadwith	Achillion partners with Janssen to boost hepatitis C pipeline Janssen will invest $225 million in Achillion shares, and has promised performance milestone payments worth up to $1.1 billion, plus royalties on any sales.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool August 27, 2009 Brian Orelli	Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool September 30, 2008 Brian Orelli	The Lethal Lessons of Eprex The FDA's concerned about J&J's blood-boosting drug. Should investors be, too?
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool March 21, 2007 Brian Lawler	Acadia Ascending Shares of Acadia Pharmaceuticals soared by more than 100% following successful results from a phase 2 trial for schizophrenia drug candidate ACP-103.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.